These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 35010976)

  • 1. Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota.
    Drożdż K; Nabrdalik K; Hajzler W; Kwiendacz H; Gumprecht J; Lip GYH
    Nutrients; 2021 Dec; 14(1):. PubMed ID: 35010976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
    Muthiah M; Ng CH; Chan KE; Fu CE; Lim WH; Tan DJH; Nah B; Kong G; Xiao J; Yong JN; Tan B; Syn N; Wang JW; Sayed N; Tan E; Chew NW; Dan YY; Siddiqui MS; Sanyal AJ; Noureddin M
    Ann Hepatol; 2023; 28(1):100762. PubMed ID: 36182031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome.
    Abenavoli L; Scarlata GGM; Scarpellini E; Boccuto L; Spagnuolo R; Tilocca B; Roncada P; Luzza F
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact.
    Alisi A; McCaughan G; Grønbæk H
    Hepatol Int; 2024 Oct; 18(Suppl 2):861-872. PubMed ID: 38995341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic-associated fatty liver disease and the risk of cardiovascular disease.
    Zhang P; Dong X; Zhang W; Wang S; Chen C; Tang J; You Y; Hu S; Zhang S; Wang C; Wen W; Zhou M; Tan T; Qi G; Li L; Wang M
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102063. PubMed ID: 36494073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
    Lee H; Lee YH; Kim SU; Kim HC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update.
    Barchetta I; Cimini FA; Cavallo MG
    Nutrients; 2020 Oct; 12(11):. PubMed ID: 33126575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.
    Adams LA; Anstee QM; Tilg H; Targher G
    Gut; 2017 Jun; 66(6):1138-1153. PubMed ID: 28314735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus.
    Bhardwaj M; Mazumder PM
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Nov; 397(11):8421-8443. PubMed ID: 38861011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease.
    Sanduzzi Zamparelli M; Compare D; Coccoli P; Rocco A; Nardone OM; Marrone G; Gasbarrini A; Grieco A; Nardone G; Miele L
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China.
    Wang Y; Yu Y; Zhang H; Chen C; Wan H; Chen Y; Xia F; Yu S; Wang N; Ye L; Lu Y
    Front Endocrinol (Lausanne); 2022; 13():968766. PubMed ID: 36120461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota in nonalcoholic fatty liver diseases with and without type-2 diabetes mellitus.
    Ebrahimzadeh Leylabadlo H; Samadi Kafil H; Farajnia S; Shanehbandi D; Yaghoub Moaddab S; Feizabadi MM; Ghotaslou R
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e548-e554. PubMed ID: 33795579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases.
    Vural H; Armutcu F; Akyol O; Weiskirchen R
    Clin Chim Acta; 2021 Dec; 523():374-379. PubMed ID: 34678296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The microbial metabolome in metabolic-associated fatty liver disease.
    Li M; Rajani C; Zheng X; Jia W
    J Gastroenterol Hepatol; 2022 Jan; 37(1):15-23. PubMed ID: 34850445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAFLD as part of systemic metabolic dysregulation.
    Zhao J; Liu L; Cao YY; Gao X; Targher G; Byrne CD; Sun DQ; Zheng MH
    Hepatol Int; 2024 Oct; 18(Suppl 2):834-847. PubMed ID: 38594474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
    Han E; Chun HS; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Lee BW; Kang ES; Cha BS; Ahn SH; Kim SU
    J Gastroenterol Hepatol; 2023 Sep; 38(9):1598-1609. PubMed ID: 37321651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.